Arformoterol
![]() | |
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide | |
| Clinical data | |
| Trade names | Brovana |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a602023 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Inhalation solution for nebuliser |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 52–65% |
| Biological half-life | 26 hours |
| Identifiers | |
| CAS Number |
67346-49-0 |
| ATC code | none |
| PubChem | CID 3083544 |
| IUPHAR/BPS | 7479 |
| DrugBank |
DB01274 |
| ChemSpider |
2340731 |
| UNII |
F91H02EBWT |
| ChEBI |
CHEBI:408174 |
| ChEMBL |
CHEMBL1201137 |
| Chemical data | |
| Formula | C19H24N2O4 |
| Molar mass | 344.405 g/mol |
| |
| | |
Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]
It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.
References
- ↑ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.
External links
- Brovana website
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, March 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

